Systematic Review and Meta-Analysis of the Utility of Circular RNAs as Biomarkers of Hepatocellular Carcinoma

Abstract EN

Emerging studies have reported circRNAs were dysregulated in HCC.

However, the clinical value of these circRNAs remains to be clarified.

Herein, we aimed to comprehensively explore their association with the diagnosis, prognosis, and clinicopathological characteristics of HCC.

PubMed, EMBASE, Web of Science, and Cochrane Library databases were comprehensively searched for eligible studies up to October 30, 2018.

The diagnostic effect was evaluated by the pooled sensitivity, specificity, and other indexes.

The pooled hazard ratio (HR) for overall survival (OS) and recurrence free survival (RFS) was calculated to assess the prognostic value.

Ten studies on diagnosis, 12 on prognosis, and 23 on clinicopathology were identified from the databases.

A total of 11 upregulated and 11 downregulated circRNAs showed an association with clinicopathological features of HCC.

For the diagnosis analyses, the pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) of circRNAs for HCC were 0.74 (95%CI: 0.65-0.82) and 0.76 (95%CI: 0.70-0.81), 3.1 (95%CI: 2.5-3.8), 0.34 (95%CI: 0.25-0.47), and 9 (95%CI: 6-14), respectively.

The area under SROC curve (AUC) was 0.81 (95% CI: 0.78–0.84), indicating moderate diagnostic accuracy.

In stratified analyses, the diagnostic performance of circRNAs varied based on the source of control and specimen type.

For the prognosis analyses, increased expression of upregulated circRNAs was associated with worse OS (HR: 3.67, 95%: 2.07-6.48), while high expression of downregulated circRNAs was associated with better OS (HR: 0.38, 95%: 0.30-0.48).

In conclusion, this study reveals that circRNAs may serve as promising diagnostic and prognostic biomarkers for HCC.

However, further investigations are still required to explore the clinical value of circRNAs.